Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:liquid_biopsy_test
|
| gptkbp:alternativeTo |
tissue biopsy
|
| gptkbp:analyzes |
circulating tumor DNA
|
| gptkbp:detects |
gptkb:HER2_mutations
ALK mutations BRAF mutations EGFR mutations ERBB2 mutations KRAS mutations MET mutations PIK3CA mutations RET mutations ROS1 mutations |
| gptkbp:developedBy |
gptkb:Inivata
|
| gptkbp:marketedIn |
gptkb:Europe
gptkb:United_States |
| gptkbp:regulates |
FDA-approved
|
| gptkbp:technology |
next-generation sequencing
|
| gptkbp:turnaroundTime |
7 days
|
| gptkbp:type |
blood
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
gptkb:cancer mutation detection genomic profiling |
| gptkbp:bfsParent |
gptkb:Inivata
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
InVisionFirst-Lung
|